{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:29:11Z","timestamp":1780471751115,"version":"3.54.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ncl.2020.09.003","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T22:11:58Z","timestamp":1604700718000},"page":"35-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.1016","volume":"39","author":[{"given":"Asya Izraelit","family":"Wallach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Kister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ncl.2020.09.003_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2020.09.003_bib2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2020.09.003_bib3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2020.09.003_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2020.09.003_bib5","unstructured":"Wingerchuck DM. Long-term safety and effectiveness of eculizumab in neuromyelitis optica spectrum disorder. Paper presented at: ECTRIMS2019. 11-13 September 2019, Stockholm, Sweden."},{"issue":"10206","key":"10.1016\/j.ncl.2020.09.003_bib6","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ncl.2020.09.003_bib7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2020.09.003_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1212\/WNL.0000000000001749","article-title":"Pushing the boundaries of neuromyelitis optica: does antibody make the disease?","volume":"85","author":"Kister","year":"2015","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2020.09.003_bib9","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00417-010-1344-7","article-title":"Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica","volume":"248","author":"Nakamura","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.ncl.2020.09.003_bib10","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.ncl.2020.09.003_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001430.pub3","article-title":"Corticosteroids for treating optic neuritis","author":"Gal","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.ncl.2020.09.003_bib12","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A\u00a0randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2020.09.003_bib13","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.ncl.2020.09.003_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.ncl.2020.09.003_bib15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/aian.AIAN_365_19","article-title":"Plasma Exchange as a First Line Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorders","volume":"22","author":"Kumawat","year":"2019","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.ncl.2020.09.003_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/787630","article-title":"Plasma Exchange in Severe Attacks of Neuromyelitis Optica","volume":"2012","author":"Bonnan","year":"2012","journal-title":"Mult Scler Int"},{"issue":"4","key":"10.1016\/j.ncl.2020.09.003_bib17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10384-018-0602-9","article-title":"Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders","volume":"62","author":"Mori","year":"2018","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ncl.2020.09.003_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.msard.2018.01.010","article-title":"Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders","volume":"20","author":"Srisupa - Olan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.003_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment Approaches for MOG-Ab-Associated Demyelination in Children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2020.09.003_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.ncl.2020.09.003_bib21","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","article-title":"A\u00a0randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis","volume":"56","author":"Noseworthy","year":"2001","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2020.09.003_bib22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1212\/01.WNL.0000152873.82631.B3","article-title":"A\u00a0double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis","volume":"64","author":"Roed","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.003_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jns.2016.11.012","article-title":"High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes","volume":"372","author":"Beh","year":"2017","journal-title":"J\u00a0Neurol Sci"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.003_bib24","article-title":"Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews","author":"Amatya","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ncl.2020.09.003_bib25","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B\u00a0lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.ncl.2020.09.003_bib26","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.003_bib27","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1212\/NXI.0000000000000188","article-title":"Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder","volume":"3","author":"Nosadini","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"10.1016\/j.ncl.2020.09.003_bib28","first-page":"2329","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Zephir","year":"2015","journal-title":"J\u00a0Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2020.09.003_bib29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"Collongues","year":"2016","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.003_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5316\/wjn.v5.i1.39","article-title":"Rituximab in neuromyelitis optica: A review of literature","volume":"5","author":"Wong","year":"2015","journal-title":"World J Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2020.09.003_bib31","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.003_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2020.09.003_bib33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.003_bib34","first-page":"57","article-title":"Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders","volume":"266","author":"Ellrichmann","year":"2019","journal-title":"J\u00a0Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2020.09.003_bib35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ncl.2020.09.003_bib36","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2020.09.003_bib37","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.msard.2019.101430","article-title":"Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders","volume":"36","author":"Novi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.ncl.2020.09.003_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neurol.2017.11.005","article-title":"Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders","volume":"174","author":"Ciron","year":"2018","journal-title":"Rev Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.003_bib39","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.ncl.2020.09.003_bib40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.003_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ncl.2020.09.003_bib42","doi-asserted-by":"crossref","first-page":"101402","DOI":"10.1016\/j.msard.2019.101402","article-title":"Rituximab-induced serum sickness in multiple sclerosis patients","volume":"36","author":"Wolf","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ncl.2020.09.003_bib43","doi-asserted-by":"crossref","unstructured":"Parrotta E, Zhovtis Ryerson L, Krupp LB. It's not always an infection: pyoderma gangrenosum of the urogenital tract in two patients with multiple sclerosis treated with rituximab. ACTRIMS Forum. West Palm Beach, FL, February 27, 2020.","DOI":"10.1212\/WNL.94.15_supplement.1795"},{"issue":"12","key":"10.1016\/j.ncl.2020.09.003_bib44","first-page":"107","article-title":"Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies","volume":"5","author":"Chen","year":"2016","journal-title":"J\u00a0Clin Med"},{"issue":"12","key":"10.1016\/j.ncl.2020.09.003_bib46","first-page":"2082","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J\u00a0Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2020.09.003_bib47","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.ncl.2020.09.003_bib48","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"3","key":"10.1016\/j.ncl.2020.09.003_bib49","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","article-title":"Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses","volume":"70","author":"Kieseier","year":"2013","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2020.09.003_bib50","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.ncl.2020.09.003_bib51","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2020.09.003_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202939","article-title":"Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab","volume":"2014","author":"Lauenstein","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"15","key":"10.1016\/j.ncl.2020.09.003_bib53","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ncl.2020.09.003_bib54","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2020.09.003_bib55","doi-asserted-by":"crossref","first-page":"e114195","DOI":"10.1371\/journal.pone.0114195","article-title":"IL-6 stimulates intestinal epithelial proliferation and repair after injury","volume":"9","author":"Kuhn","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ncl.2020.09.003_bib56","doi-asserted-by":"crossref","first-page":"101920","DOI":"10.1016\/j.msard.2019.101920","article-title":"Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders","volume":"39","author":"Lotan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"22","key":"10.1016\/j.ncl.2020.09.003_bib57","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"Pt 7","key":"10.1016\/j.ncl.2020.09.003_bib59","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A\u00a0role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.ncl.2020.09.003_bib60","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2020.09.003_bib61","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2020.09.003_bib62","first-page":"1","article-title":"Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder","author":"Avasarala","year":"2019","journal-title":"CNS Spectr"},{"issue":"8","key":"10.1016\/j.ncl.2020.09.003_bib63","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.ncl.2020.09.003_bib64","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"issue":"15","key":"10.1016\/j.ncl.2020.09.003_bib65","doi-asserted-by":"crossref","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","article-title":"Evaluation of efficacy and tolerability of first-line therapies in NMOSD","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.003_bib66","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"issue":"4","key":"10.1016\/j.ncl.2020.09.003_bib67","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.ncl.2020.09.003_bib68","first-page":"2003","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J\u00a0Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2020.09.003_bib69","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2020.09.003_bib70","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ncl.2020.09.003_bib71","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/rheumatology\/kei263","article-title":"Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment","volume":"45","author":"Falcini","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ncl.2020.09.003_bib72","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2020.09.003_bib73","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.003_bib74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12883-018-1056-x","article-title":"Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study","volume":"18","author":"Jiao","year":"2018","journal-title":"BMC Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2020.09.003_bib75","first-page":"111","article-title":"What Is the Teratogenic Risk of Mycophenolate?","volume":"6","author":"Kylat","year":"2017","journal-title":"J\u00a0Pediatr Genet"},{"issue":"2","key":"10.1016\/j.ncl.2020.09.003_bib76","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cen3.12189","article-title":"Methotrexate is effective for the treatment of neuromyelitis optica spectrum disorders in Asian patients","volume":"6","author":"Ng","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"issue":"8","key":"10.1016\/j.ncl.2020.09.003_bib77","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","article-title":"Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies","volume":"84","author":"Kitley","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2020.09.003_bib78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7224\/1537-2073-2.4.43","article-title":"Treatment of Devic's Disease with Methotrexate and Prednisone","volume":"2","author":"Minagar","year":"2000","journal-title":"Int J MS Care"},{"key":"10.1016\/j.ncl.2020.09.003_bib79","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2377-14-51","article-title":"Treatment of neuromyelitis optica\/neuromyelitis optica spectrum disorders with methotrexate","volume":"14","author":"Ramanathan","year":"2014","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2020.09.003_bib80","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/1352458514546793","article-title":"Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders","volume":"21","author":"Tanaka","year":"2015","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.003_bib81","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41598-017-00860-y","article-title":"Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ncl.2020.09.003_bib83","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2019.04.007","article-title":"Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review","volume":"332","author":"Enriquez","year":"2019","journal-title":"J\u00a0Neuroimmunol"},{"issue":"Pt 11","key":"10.1016\/j.ncl.2020.09.003_bib84","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"issue":"21","key":"10.1016\/j.ncl.2020.09.003_bib85","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1212\/WNL.0b013e318238ee00","article-title":"Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone","volume":"77","author":"Martinelli","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2020.09.003_bib86","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/1352458508100967","article-title":"Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?","volume":"15","author":"Ellis","year":"2009","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.ncl.2020.09.003_bib87","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp-2012-303121","article-title":"Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study","volume":"84","author":"Cabre","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2020.09.003_bib88","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study","volume":"370","author":"Xu","year":"2016","journal-title":"J\u00a0Neurol Sci"},{"issue":"7","key":"10.1016\/j.ncl.2020.09.003_bib89","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneurol.2012.545","article-title":"Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients","volume":"69","author":"Bichuetti","year":"2012","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2020.09.003_bib90","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458514541978","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party","volume":"21","author":"Greco","year":"2015","journal-title":"Mult Scler"},{"issue":"18","key":"10.1016\/j.ncl.2020.09.003_bib91","doi-asserted-by":"crossref","first-page":"e1732","DOI":"10.1212\/WNL.0000000000008394","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica","volume":"93","author":"Burt","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ncl.2020.09.003_bib92","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jocn.2015.02.007","article-title":"Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant","volume":"22","author":"Aouad","year":"2015","journal-title":"J\u00a0Clin Neurosci"},{"issue":"7","key":"10.1016\/j.ncl.2020.09.003_bib93","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"15 Supplement","key":"10.1016\/j.ncl.2020.09.003_bib94","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1212\/WNL.94.15_supplement.4540","volume":"94","author":"Sharrack","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2020.09.003_bib95","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.ncl.2020.09.003_bib96","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.ncl.2020.09.003_bib97","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.003_bib98","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.ncl.2020.09.003_bib99","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.003_bib100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458512470730","article-title":"Piet Mondrian's trees and the evolution in understanding multiple sclerosis, Charcot Prize Lecture 2011","volume":"19","author":"Steinman","year":"2013","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.ncl.2020.09.003_bib101","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1212\/NXI.0000000000000276","article-title":"Restoring immune tolerance in neuromyelitis optica: Part I","volume":"3","author":"Steinman","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.ncl.2020.09.003_bib102","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1212\/NXI.0000000000000277","article-title":"Restoring immune tolerance in neuromyelitis optica: Part II","volume":"3","author":"Bar-Or","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:20:40Z","timestamp":1760005240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861920300700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0733861920300700"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2020.09.003","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2020.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}